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Abstract  
 
Background: There is little research on how people with dementia are involved in 
treatment decisions at diagnosis. 
 
Objective: To measure shared decision making when starting cholinesterase 
inhibitors, investigate associations with contextual factors and explore satisfaction 
and experience of the diagnostic meeting. 
 
Setting: Nine UK memory clinics in two geographical locations. 
 
Subjects: 74 people receiving dementia diagnoses (with 69 companions) and 21 
doctors. 
 
Methods: We video-recorded 74 memory clinic consultations and rated doctor shared 
decision making behaviours using the Observing Patient Involvement in Decision 
Making scale (OPTION-5 scale). Patients and companions rated their satisfaction and 
experience. Mixed-effects regressions investigated involvement and (1) number 
people present, meeting length, capacity, cognitive functioning, diagnosis; and (2) 
patient/companion satisfaction and consultation experience. 
 
Results: Mean consultation time was 26.7 minutes. Mean OPTION-5 score was 
22.5/100 (Standard Deviation =17.3). Doctors involved patients in decisions more 
often when patients had mixed dementia (β=10.13, 95% confidence interval 1.25 to 
  
19.0, p=.025) and in shorter meetings (β= -0.51, 95% CI -0.87 to -0.15, p=.006). 
Patient and companion satisfaction were high and not associated with whether 
doctors invited patient involvement. Half of patients and one-third companions were 
uncertain about the meeting outcome, experienced communication barriers and 
negative emotions. 
 
Conclusions: Consultations scored low on shared decision making, but were compa-
rable to other settings and were not lower with more cognitively impaired patients.  
Negative patient and companion experiences reflect the importance of supporting 
health care providers to address patient and companion emotions and need for infor-
mation.  
 
  
  
Background 
 
How clinicians approach treatment discussions at dementia diagnosis can empower 
people to be involved in healthcare planning [1-3]. Shared decision making involves 
two-way information exchange between patient and clinician to arrive at a consensus 
about treatment [4]. It can increase satisfaction, treatment adherence and improve 
clinical outcomes [5,6]. There are challenges to shared decision making that may be 
further complicated with cognitive impairment [7]. However, lack of capacity due to 
dementia should not be assumed [8,9]. Patients with dementia wish to be involved in 
healthcare decisions [10] and express consistent preferences to be involved even 
with moderate cognitive impairment [11].  
 
Medication decisions are often made when patients are informed that they have 
dementia, providing a window through which to observe how involved people with 
dementia are in decision making. There are few studies examining how decisions are 
made about whether to start cholinesterase inhibitors [12,13]. In this study, we used 
the Observing Patient Involvement in Decision Making scale [14], a widely used 
shared decision making coding scheme that has not been used with dementia 
diagnosis consultations. Using a standardised scale allowed us to explore 
associations with contextual factors and make comparisons with other settings.     
 
 
Methods 
 
Study design and setting 
ShareD was an NIHR funded observational study collecting data from memory clinic 
diagnostic feedback meetings in two UK geographical locations (Study ID: PB-PG-
1111-26063). Recruitment ran from May 2014 to April 2017. Camden and Islington 
Research Ethics Committee provided ethical approval (13/LO/1309). 
  
 
Participants and recruitment 
 
All doctors delivering diagnoses of dementia were eligible. The exclusion criteria for 
patients were age 65 and the need for an interpreter.  
 
Doctors were contacted by the study team and those interested in participating 
provided written informed consent. Patients scheduled for a diagnostic feedback were 
informed of the study with their appointment letters and informed consent was 
obtained at clinic. Doctors assessed patient capacity to provide informed consent. 
Where patients lacked capacity Department of Health Guidance on nominating a 
consultee was followed [15].  
 
Data collection 
 
Diagnosis meetings were video-recorded. The researcher was not present. The 
number of people present and meeting length (in minutes) were confirmed using the 
recordings. The following measures were used: 
 
Doctor involvement of patients in decision making 
Video recordings were observer-rated by two trained researchers using the OPTION-
5 [14]. This is the updated version of the OPTION-12, which the OPTION authors 
provided permission to use prior to its publication. The OPTION-5 consists of five 
items rating whether the doctor (1) describes different treatment options; (2) supports 
the patient in becoming informed; (3) checks understanding of all reasonable options; 
(4) supports patients to examine preferences; and (5) integrates patient preferences 
into the decision.  Each item is rated from 0 (“no effort”), 1 (“minimal effort”), 2 
  
(“moderate effort”), 3 (“good effort”) to 4 (“exemplary effort”) generating a total score 
of 0-20, rescaled to 0-100. The OPTION-5 is a valid and reliable measure of shared 
decision-making [16]. The researchers doing the rating were blinded to the other 
outcome measures. 22% of the videos (n=16) were rated by both researchers to test 
inter-rater reliability. 
 
Cognitive Test Scores 
Doctors administered the Mini Mental State Exam [17] or Addenbrooke’s Cognitive 
Examination III [18] as part of their routine assessment.  
 
Diagnosis and Capacity 
Doctors recorded patient diagnosis and capacity to make treatment decisions. 
Capacity was indicated as ‘none’ or ‘full’. 
 
Patient Autonomy 
Patients and companions completed the decision-making subscale of the Autonomy 
Preference Index [19] to evaluate patient preference for participation in decisions. The 
scale consists of six statements rated on from 1 “Strongly disagree” to 5 “Strongly 
agree”. 
 
Patient and Companion Satisfaction 
Patients and companions filled out the Satisfaction with Decision scale [20], which 
measures satisfaction with health care decisions and consists of six items rated from 
1 “Strongly disagree” to 5 “Strongly agree”. The possible scores range from 6 to 30.  
 
Patient and Companion Experience 
The Patient Experience Questionnaire [21] is an 18-item questionnaire consisting of 
five subscales: (1) Outcomes of consultation (2) Communication with the doctor (3) 
  
Emotions (4) Barriers to communication and (5) Auxiliary experience. The subscales 
are rated on a 5-point Likert scale except for the Emotion subscale rated on a 7-point 
scale. In the present study the Emotion scale comprised only three items (i.e. Sad-
cheerful; Worn-out - strengthened; Worried - relieved), so the total PEQ score ranges 
from 17 to 91. 
 
Data Analysis 
The target sample size was 75 patients and 15 clinicians. This was calculated based 
on 3 predictors in a multiple regression analysis, ensuring the study was powered to 
detect a medium effect size (f2=0.15/ r=0.36) on the strength of the relationships 
between the predictors and involvement in shared decision making with 80% power, 
p=0.05. 
 
Due to low frequencies (see Table 1), number of people present was recoded as a 
binary variable (Number of people present ≤3 or >3) and only Alzheimer’s disease 
and Mixed dementia were included in the analysis. 
 
Descriptive statistics were explored. Cronbach’s alpha was calculated for 
questionnaires to determine internal consistency. Sum PEQ scores were calculated 
by summing individual items and dividing by the number of items within each scale. 
Histograms were produced to assist interpretation [21], scores below the subscale’s 
midpoint were interpreted as indicating concerns. 
 
To examine whether number of people, meeting length, patient decision-making 
capacity, cognitive functioning, and diagnosis were associated with OPTION-5 score, 
a linear mixed-effects regression model accounting for clustering on the doctor level 
(i.e. random effect) was estimated for each independent variable with OPTION as the 
  
dependent variable. Next, statistically significant variables at p<0.1 were entered into 
a multiple regression mixed-effects model with OPTION-5 score as the dependent 
variable. 
 
To examine whether OPTION-5 score was associated with satisfaction and 
experience, two linear mixed-effects regression models were estimated with OPTION 
score as the independent variable and patient and companion satisfaction and 
experience as the dependent variables. 
 
Results 
 
Participants 
Participant sociodemographic information can be found in Table 1. Participant flow is 
described in Figure 1. 215 patients were recruited (consent rate 51%). 101 people 
were diagnosed with dementia and in 75 meetings there was a decision about starting 
cholinesterase inhibitors. One patient was excluded as they were aged under 65, 
resulting in a sample of 74 patients and 69 companions. Most participants were 
diagnosed with Alzheimer’s disease (70%), followed by Mixed dementia (19%). A 
Mixed dementia diagnosis indicates that features of Alzheimer’s disease and Vascular 
dementia are present (coded in ICD-10 as Alzheimer’s disease, atypical or mixed type 
(F00.2)). 
 
Table 1: Participant characteristics. 
 
Characteristic 
Patients (n=74) 
N (%) or mean (SD) 
Companions (n=69) 
N (%) or mean (SD) 
Site  
 
London 31 (42%) 26 (37.7%) 
Devon 43 (58%) 43 (62.3%) 
Gender   
 
Male 29 (39%) 30 (57%) 
  
Female 45 (61%) 39 (43%) 
Age   
 81.7 (6.3) 
Range 65 to 91 
63.6 (15.8) 
Range 26 to 90 
Marital status   (n=68) 
Single 2 (3%) 12 (18%) 
Married/Partnership 41 (55%) 49 (72%) 
Separated 2 (3%) -- 
Divorced 11 (15%) 4 (6%) 
Widowed 18 (24%) 3 (4%) 
Ethnicity  (n=72) (n=68) 
White British 58 (80%) 57 (84%) 
White Irish 3 (4%) 1 (2%) 
White Other 3 (4%) 2 (3%) 
Asian or Asian British -- 1 (2%) 
Black or Black British 1 (2%) 2 (3%) 
Caribbean 3 (4%) 3 (4%) 
African 1 (2%) -- 
Black other -- 1 (2%) 
Any Other 3 (4%) 1 (2%) 
Education level  (n=71) (n=68) 
School (GCSE) 43 (61%) 27 (40%) 
Further Education (A-level) 15 (21%) 19 (28%) 
Higher Education (beyond A-level) 13 (18%) 22 (32%) 
Diagnoses received  
Alzheimer's dementia 
Mixed dementia 
Parkinson's disease dementia 
Unspecified dementia 
Lewy body dementia 
52 (70%) 
14 (19%) 
2 (3%) 
4 (5%) 
2 (3%) 
 
Capacity  
 
 
None 20 (27%)  
Full 44 (60%)  
Missing 10 (13%)  
 
 
Companions were spouses/partners (n=30, 40%), children/children in law (n=27, 
36%), siblings (n=2) and friends (n=2). Eight 8 identified as ‘other’. Five patients (7%) 
were not accompanied.  
 
Twenty-one doctors participated in the study (consent rate 88%). They were 
consultant psychiatrists (n=15) or geriatricians (n=3), psychiatry registrars (n=2) and 
  
one speciality doctor in psychiatry. In 49 (66%) consultations there was just the doctor 
present. In 24 (32%) there was an additional clinician and in one there were two 
additional clinicians. These were social workers (n=9) dementia support workers 
(n=6), nurses (n=4), registrars (n=4) and medical students (n=3). 
 
Figure 1. Study recruitment flow chart. 
 
 
 
 
 
 
Measures 
Mean consultation time was 26.7 minutes. Descriptive findings for each measure are 
presented in Table 2. 
 
  
Table 2: Statistics for study variables and Mixed multiple regression mixed effect 
model. 
Measure N % or mean (SD) Range  
OPTION score (rescaled to 1-100)  
74 22.50 (17.25) 0 to 90 
Item 1 ‘Presenting multiple options’ 74 0.86 (0.88) 0 to 3 
Item 2 ‘Establishing partnership’ 74 0.34 (0.69) 0 to 4 
Item 3 ‘Check understanding of all options’ 74 1.32 (0.86) 0 to 4 
Item 4 ‘Examine preferences’ 74 1.04 (1.05) 0 to 4 
Item 5 ‘Integrating preferences’ 74 0.93 (1.00) 0 to 4 
Number of people present in meeting* (n=74)  
2 people 1 1.35%  
3 people 46 62.16%  
4 people 22 29.73%  
5 people 3 4.05%  
6 people 2 2.70%  
Meeting length 74 
27m 40s  
(9m 36s) 
7m 25s to 
54m 22s 
Patient capacity (n=64)    
None 3 4.69%  
Partial 17 26.56%  
Full 44 68.75%  
Cognitive test score (n=70)    
ACE-III (out of 100) 61 68.39 (11.57) 41 to 94 
MMSE (out of 30) 12 23.08 (4.64) 15 to 28 
API (out of 100) 68 46.91 (12.37) 20 to 75 
Patient SWD (out of 30)         56 24.45 (2.00) 17 to 29 
Companion SWD (out of 30)        42 25.26 (3.04) 19 to 30 
Patient PEQ    
Outcome (out of 5) 57 3.01 (0.86) 1.25 to 5 
Communication (out of 5) 66 4.18 (0.54) 2.5 to 5 
Barriers (out of 5)  68 3.13 (0.67) 1.5 to 4.25 
Auxiliary (out of 5) 64 4.01 (0.75) 2 to 5 
Emotions (out of 7) 67 4.09 (0.66) 3 to 5.67 
Total (out of 27) 51 20.76 (2.43) 15.5 to 25.75 
Companion PEQ (out of 91)    
Outcome (out of 5)  64 3.46 (0.80) 2 to 5 
Communication (out of 5)  62 4.46 (0.49) 3.5 to 5 
Barriers (out of 5)  62 3.56 (0.49) 2.25 to 4 
Auxiliary staff (out of 5)  61 4.34 (0.73) 2.5 to 5 
Emotion (out of 7)  60 4.78 (0.74) 3 to 6.67 
  
Total 57 23.03 (2.11) 18.25 to 26.5 
Mixed Effects model 
                                                          Variable Beta (β) 95% Confidence 
Interval 
P-value 
Meeting length -0.51 -0.87 to -0.15 .006 
Diagnosis 10.13 1.25 to 19.00 .025 
Number of adults -6.79 -14.32 to 0.73 .077 
 
 
Internal Consistency 
Internal consistency of scales was estimated using Cronbach’s alpha. OPTION-5 
Cronbach’s alpha was .82. The remaining Cronbach’s alpha scores were (for patients 
and companions respectively): .65 and .90 for the SWD scale; .62 and .71 for the 
PEQ Outcome subscale; .77 and .80 for the PEQ Barriers subscale; .67 and .72 for 
the PEQ Emotion subscale and .63 and .80 for the PEQ Communication subscale. 
Although internal consistency of patient rated scales was borderline acceptable, they 
were retained for analysis given the exploratory nature of this study.  
 
The API and patient and companion PEQ Auxiliary subscales had poor internal 
consistency (alpha= .60, .58, and .53, respectively) and were not used in further 
analyses. 
 
Doctor involvement of patients in decision making 
Cohen’s weighted kappa demonstrated substantial agreement between OPTION-5 
raters (κ=0.75). The mean OPTION-5 score was 22.50/100. Mean item scores (see 
Table 2) were highest for item 3 ‘describing the pros and cons and checking 
understanding’ (mean=1.32) and item 4 ‘examining patient preferences’ (1.04), lower 
  
for ‘integrating preferences’ (0.93), ‘presenting multiple options’ (0.86) and lowest for 
item 2 ‘supporting patients to be informed’ (0.34). 
 
Satisfaction with Communication 
Patient and companion scores on the SWD scale were mean 24.45 (SD 2.00) and 
25.26 (SD 3.04) respectively. Over 90% of patient and companion ratings were at 
least 4 out of 5. 
 
PEQ scores were more varied. 59.7% of patients and 35.9% of companions 
expressed uncertainty on the Outcome scale (i.e. mean scores at or below midpoint). 
51.5% of patients and 26.8% of companions reported barriers to communication 
(Barriers scale).  On the Emotion scale, 53% of patients and 21.7% of companions 
felt negative or no positive emotion. On the Communication scale, 4.6% of patients 
and no companions described communication as less than optimal.  
 
Bivariate Associations 
 
A significant association between the number of people present and OPTION-5 score 
was identified (β=8.56, 95% CI -16.55 to -0.57, p=.03), indicating that doctors invited 
less patient involvement when there were more than three people present. 
 
There was a statistically significant inverse association between the length of the 
meeting in minutes and OPTION-5 score (β= -0.47, 95% CI -0.89 to -0.06, p=.02). 
This means that there was a 0.47-point decrease in involvement in decisions with 
each additional minute in length of the meeting  
The mean OPTION-5 score in patients with None/Partial capacity to make treatment 
decisions was 25.5 (SD=18.63) and in those with Full capacity was 21.25 
  
(SD=17.66). No significant association was identified (β=-4.25, 95% CI -13.93 to 5.43, 
p=.31). 
 
There was no evidence that OPTION-5 score was associated with cognitive 
impairment on the MMSE (n=12; p=.33) or ACE-III (n=61; p=.78). 
 
The mean OPTION-5 score was 31.4 (SD=22.8) and 19.7 (SD=14.2) for patients with 
Mixed dementia and Alzheimer’s disease, respectively. This was a statistically 
significant association (β=9.39, 95%CI 0.05 to 18.72, p=.05). 
 
We observed no significant association between OPTION-5 score and patient or 
companion satisfaction with the decision (SWD, p=0.34 and p=0.71 respectively), or 
subscale and total experience scores (PEQ, patients all p values≥0.49, companions 
all p values≥0.58). 
 
Multiple regression mixed-effects model 
 
 
Significant predictors on a bivariate level (meeting length, diagnosis received and 
number present) were entered into a multiple regression model with the doctor 
included as a random effect and OPTION-5 as the dependent variable (Table 2).  
Doctors involved patients in decisions more often when patients had mixed dementia 
(β=10.13, 95% confidence interval 1.25 to 19.0, p=.025) and in shorter meetings (β= -
0.51, 95% CI -0.87 to -0.15, p=.006). 
 
 
 
 
Discussion 
 
  
 
Shared decision making scores about dementia medication were low, with a mean of 
22.5/100 on the OPTION scale [22]. Involvement was higher when patients had 
Mixed dementia diagnoses rather than Alzheimer’s disease, and in shorter meetings. 
Cognitive impairment and capacity were not observed to impact shared decision 
making. Satisfaction was high, but half of patients and one third of companions 
reported negative experiences.  
 
While shared decision making scores were low, they were similar to other settings. A 
systematic review of OPTION-12 found only 38% of studies have average scores 
over 25/100 and almost all are under 50 [23]. Hence, low involvement appears not to 
be due to dementia. Alongside the fact that capacity and cognitive test scores did not 
impact on scores, this demonstrates doctor willingness to include people with 
dementia in decisions. However, it does suggest there is room for increasing patient 
involvement in decision making across all medical settings.  
 
It is important to reflect on the OPTION tool as a measure of shared decision making. 
We observed no significant association between OPTION scores and satisfaction or 
experience. A 2015 review found that in the 6 studies linking observer rated measures 
of shared decision making with outcomes, only two found associations, with one 
showing improved satisfaction with higher OPTION scores [24]. Our concept of 
shared decision making is intricately linked to how it is measured. A study by this 
team using a more fine-grained approach to analysis found lower satisfaction scores 
when doctors recommended treatment in a more directive way (i.e. “I will prescribe a 
medication” versus “would you like to try a medication”) [25]. This highlights the 
methodological challenges of assessing shared decision making [26], specifically the 
level of detail that is captured in how doctors communicate. 
 
  
Patient experience of the diagnosis meeting was somewhat negative, in line with 
other studies of dementia diagnosis [27]. This diagnostic context may explain why 
doctors scored lower on integrating patient preferences for not taking medication, 
doctors wish to offer hope at diagnoses and medication has this symbolic value [28]. 
Doctors are concerned about overwhelming patients [13]. However, patient well-being 
is affected by the perceived quality of disclosure [29]. Half of patients and one third of 
companions had limited understanding of dementia and experienced barriers in 
communication. Hence, it may be that doctors need support to balance understanding 
and hope in delivering dementia diagnoses [30,31].  
 
While previous studies have found more involvement in longer meetings [23], or no 
association [6], we found less involvement in longer meetings. Longer meetings may 
reflect other factors, e.g. increased complexity due to diagnostic uncertainty leaving 
less time for decision-making.  Patients diagnosed with Mixed dementia were more 
involved in decision-making compared with Alzheimer’s disease alone. Identifying the 
patient, companion and clinician factors underlying this should be explored in future 
research. 
 
The findings should be considered in the light of the study’s strengths and limitations. 
Strengths include the first empirical analysis of decision-making in dementia, using 
the validated OPTION scale, observer-rated using video recordings. We captured 
multiple facets of patient and companion perception to reduce methodological 
challenges of satisfaction research. However, we could not include the API in the 
analysis due to poor internal consistency, which has also been the case in other 
patient populations [32]. The study was powered to detect medium relationships 
between variables (r=.35), and the internal consistency of some of the included scales 
were modest. Categorial variables (patient capacity, number of people present, 
diagnosis) are less sensitive than continuous variables, impacting on the likelihood of 
  
detecting associations. Finally, some self-report scales may be rendered invalid when 
MMSE scores are below 20 [32]. While most patients were tested using the ACE-III, 
three patients scored <20 on the MMSE. 
 
To conclude, while OPTION-5 scores were low, they were comparable to other set-
tings and were not lower with more cognitively impaired patients. Nonetheless, there 
is scope for increasing involvement of people with dementia in decisions. Healthcare 
providers should be aware that although they elicit patient preferences, these are not 
always incorporated into the final decision. Half of patients and one third of compan-
ions reported negative experiences of receiving a diagnosis of dementia. Supporting 
healthcare providers in communication may address an unmet need for emotional 
support and adequate information at diagnosis.  
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